1. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T . Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy Leukemia 1990 4: 184–188
2. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M . A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia Blood 1996 88: 756
3. Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei E III . The effect of chemotherapy on acute leukemia in the human J Chron Dis 1961 14: 593
4. Estey E, Shen Y, Thall PF . Effect of time to achieve CR on subsequent survival time and disease-free survival time in patients with AML, RAEB-t, or RAEB in whom response is established after the first course of chemotherapy Blood (in press)
5. Vey N, Keating M, Giles F, Cortes J, Beran M, Estey E . Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy Blood 1999 93: 3149–3150